T80.A11A Non-ABO incompatibility with delayed hemolytic transfusion reaction, initial encounter

Name of the Condition

• Non-ABO incompatibility with delayed hemolytic transfusion reaction, initial encounter.

Summary

This condition describes a delayed hemolytic transfusion reaction resulting from non-ABO blood group incompatibility during the initial encounter. It occurs when the recipient’s immune system reacts to non-ABO antigens in transfused blood or blood products, leading to hemolysis that typically manifests days to weeks after transfusion. The "initial encounter" designation indicates this is the first time the patient is being seen for this specific reaction.

Causes

Delayed hemolytic transfusion reactions due to non-ABO incompatibility are caused by immune responses to minor blood group antigens (e.g., Rh, Kell, Duffy, or Kidd systems) or antibodies against platelet or plasma proteins. These reactions may result from prior sensitization through pregnancy, previous transfusions, or organ transplants, where the recipient has developed antibodies against these antigens. The reaction is triggered when incompatible blood is transfused, leading to delayed immune-mediated destruction of transfused red blood cells.

Risk Factors

• Prior exposure to incompatible blood products
• History of multiple transfusions or pregnancies
• Underlying immune-mediated conditions
• Use of blood products with non-ABO antigen mismatches
• Lack of pre-transfusion antibody screening in high-risk patients

Symptoms

• Fever, chills, or rigors
• Jaundice or dark urine
• Unexplained anemia
• Elevated bilirubin or LDH levels
• Mild hemoglobinuria

Diagnosis

Diagnosis involves clinical evaluation of symptoms occurring days to weeks post-transfusion, laboratory testing for hemolysis (e.g., elevated bilirubin, LDH, reticulocytosis), and antibody screening to identify non-ABO antibodies. Transfusion records and prior sensitization history are reviewed to confirm the reaction’s timing and cause. Direct antiglobulin testing may detect antibodies bound to red blood cells.

Treatment Options

Management focuses on supportive care, including monitoring for hemolysis and anemia, and addressing complications such as renal impairment. Transfusion of compatible blood products may be required if anemia is severe. Corticosteroids or other immunosuppressants are rarely used but may be considered in severe cases. Discontinuation of the offending transfusion is essential.

Prognosis and Follow-Up

Most delayed hemolytic reactions are mild and resolve with supportive care. Prognosis is generally favorable, but severe cases may lead to renal failure or other complications. Follow-up includes monitoring hemoglobin levels, bilirubin, and renal function. Patients should avoid future transfusions with incompatible antigens, and antibody screening should guide future transfusions.

Complications

• Acute kidney injury
• Severe anemia requiring transfusion
• Disseminated intravascular coagulation (rare)
• Transfusion-related acute lung injury (TRALI, rare)

Lifestyle & Prevention

• Ensure accurate blood typing and crossmatching before transfusion.
• Use leukoreduced blood products to reduce immune sensitization.
• Screen for non-ABO antibodies in high-risk patients (e.g., those with prior transfusions or pregnancies).
• Educate patients on the importance of reporting post-transfusion symptoms promptly.

When to Seek Professional Help

Seek immediate medical attention if symptoms such as fever, jaundice, dark urine, or unexplained fatigue occur after a transfusion, especially if they develop days to weeks later. Prompt evaluation is critical to manage hemolysis and prevent complications.

Tips for Medical Coders

Code T80.A11A is used for the initial encounter of a delayed hemolytic transfusion reaction due to non-ABO incompatibility. Documentation should specify the reaction’s timing (delayed), the non-ABO antigen involved (if known), and that this is the first encounter for the reaction. Ensure the encounter is clearly documented as "initial" to justify the code.